Defence Therapeutics Inc. Cash Flow Conversion Efficiency
Defence Therapeutics Inc. cash flow conversion efficiency. Based on the latest financial reports, Defence Therapeutics Inc. (DTC) has a cash flow conversion efficiency ratio of 1.144x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.40 Million ≈ $-1.64 Million USD) by net assets (€-1.22 Million ≈ $-1.43 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Defence Therapeutics Inc. (2020–2024)
Cash flow conversion efficiency of Defence Therapeutics Inc. from 2020 to 2024. This chart illustrates how Defence Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View DTC live share price for real-time trading data and today's change.
Defence Therapeutics Inc. Cash Flow Conversion Ratio Explained
Defence Therapeutics Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Defence Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Defence Therapeutics Inc. ranked by their cash flow conversion efficiency. Also see DTC company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SenzaGen AB
ST:SENZA
|
-0.052x |
|
Immo Moury SICAF Immobiliere Publique de Droit Belge
BR:IMMOU
|
0.026x |
|
Lion Forest Industries Bhd
KLSE:8486
|
-0.011x |
|
DF Deutsche Forfait AG
XETRA:DFTK
|
-0.210x |
|
Greencore Group
LSE:GNC
|
0.221x |
|
Olympia Industries Bhd
KLSE:3018
|
-0.015x |
|
CSLM Acquisition Corp.
NASDAQ:CSLMF
|
-0.046x |
|
Ascent Solar Technologies, Inc.
NASDAQ:ASTI
|
-0.065x |
Annual Cash Flow Conversion Efficiency for Defence Therapeutics Inc. (2020–2024)
The table below shows the annual cash flow conversion efficiency of Defence Therapeutics Inc. from 2020 to 2024. Review Defence Therapeutics Inc. (DTC) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-06-30 | €-3.58 Million ≈ $-4.19 Million |
€-4.29 Million ≈ $-5.01 Million |
1.196x | +124.47% |
| 2023-06-30 | €1.57 Million ≈ $1.83 Million |
€-7.66 Million ≈ $-8.95 Million |
-4.889x | -131.35% |
| 2022-06-30 | €-387.56K ≈ $-453.10K |
€-6.04 Million ≈ $-7.07 Million |
15.596x | +3837.50% |
| 2021-06-30 | €5.49 Million ≈ $6.41 Million |
€-2.29 Million ≈ $-2.68 Million |
-0.417x | -485.46% |
| 2020-06-30 | €1.86 Million ≈ $2.18 Million |
€-132.83K ≈ $-155.29K |
-0.071x | -- |
About Defence Therapeutics Inc.
Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting vario… Read more